Literature DB >> 33479683

Structure-guided discovery of selective methionyl-tRNA synthetase inhibitors with potent activity against Trypanosoma brucei.

Zhongsheng Zhang1, Ximena Barros-Álvarez1, J Robert Gillespie2, Ranae M Ranade2, Wenlin Huang1, Sayaka Shibata1, Nora M R Molasky2, Omeed Faghih2, Aisha Mushtaq2, Robert K M Choy3, Eugenio de Hostos3, Wim G J Hol1, Christophe L M J Verlinde1, Frederick S Buckner2, Erkang Fan1.   

Abstract

Based on crystal structures of Trypanosoma brucei methionyl-tRNA synthetase (TbMetRS) bound to inhibitors, we designed, synthesized, and evaluated two series of novel TbMetRS inhibitors targeting this parasite enzyme. One series has a 1,3-dihydro-imidazol-2-one containing linker, the other has a rigid fused aromatic ring in the linker. For both series of compounds, potent inhibition of parasite growth was achieved with EC50 < 10 nM and most compounds exhibited low general toxicity to mammalian cells with CC50s > 20 000 nM. Selectivity over human mitochondrial methionyl tRNA synthetase was also evaluated, using a cell-based mitochondrial protein synthesis assay, and selectivity in a range of 20-200-fold was achieved. The inhibitors exhibited poor permeability across the blood brain barrier, necessitating future efforts to optimize the compounds for use in late stage human African trypanosomiasis. This journal is © The Royal Society of Chemistry 2020.

Entities:  

Year:  2020        PMID: 33479683      PMCID: PMC7649832          DOI: 10.1039/d0md00057d

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  24 in total

Review 1.  The blood-brain barrier: bottleneck in brain drug development.

Authors:  William M Pardridge
Journal:  NeuroRx       Date:  2005-01

2.  Human African trypanosomiasis.

Authors:  Reto Brun; Johannes Blum; Francois Chappuis; Christian Burri
Journal:  Lancet       Date:  2009-10-14       Impact factor: 79.321

3.  Structure-guided design of novel Trypanosoma brucei Methionyl-tRNA synthetase inhibitors.

Authors:  Wenlin Huang; Zhongsheng Zhang; Ximena Barros-Álvarez; Cho Yeow Koh; Ranae M Ranade; J Robert Gillespie; Sharon A Creason; Sayaka Shibata; Christophe L M J Verlinde; Wim G J Hol; Frederick S Buckner; Erkang Fan
Journal:  Eur J Med Chem       Date:  2016-10-14       Impact factor: 6.514

4.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

Review 5.  Trypanocidal drugs: mechanisms, resistance and new targets.

Authors:  Shane R Wilkinson; John M Kelly
Journal:  Expert Rev Mol Med       Date:  2009-10-29       Impact factor: 5.600

6.  Variable sensitivity to bacterial methionyl-tRNA synthetase inhibitors reveals subpopulations of Streptococcus pneumoniae with two distinct methionyl-tRNA synthetase genes.

Authors:  Daniel R Gentry; Karen A Ingraham; Michael J Stanhope; Stephen Rittenhouse; Richard L Jarvest; Peter J O'Hanlon; James R Brown; David J Holmes
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

Review 7.  Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness).

Authors:  Peter Ge Kennedy
Journal:  Lancet Neurol       Date:  2012-12-21       Impact factor: 44.182

8.  Relationship between specific gravity, water content, and serum protein extravasation in various types of vasogenic brain edema.

Authors:  H W Bothe; W Bodsch; K A Hossmann
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

9.  The European Medicines Agency's scientific opinion on oral fexinidazole for human African trypanosomiasis.

Authors:  Eric Pelfrene; Martin Harvey Allchurch; Nsengi Ntamabyaliro; Victoria Nambasa; Fátima V Ventura; Nithyanandan Nagercoil; Marco Cavaleri
Journal:  PLoS Negl Trop Dis       Date:  2019-06-27

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  3 in total

1.  Physiologic Targets and Modes of Action for CBL0137, a Lead for Human African Trypanosomiasis Drug Development.

Authors:  Carlos E Sanz-Rodriguez; Benjamin Hoffman; Paul J Guyett; Andrei Purmal; Baljinder Singh; Michael Pollastri; Kojo Mensa-Wilmot
Journal:  Mol Pharmacol       Date:  2022-05-23       Impact factor: 4.054

2.  Fragment screening and structural analyses highlight the ATP-assisted ligand binding for inhibitor discovery against type 1 methionyl-tRNA synthetase.

Authors:  Jia Yi; Zhengjun Cai; Haipeng Qiu; Feihu Lu; Zhiteng Luo; Bingyi Chen; Qiong Gu; Jun Xu; Huihao Zhou
Journal:  Nucleic Acids Res       Date:  2022-04-26       Impact factor: 19.160

Review 3.  Aminoacyl-tRNA Synthetases as Valuable Targets for Antimicrobial Drug Discovery.

Authors:  Luping Pang; Stephen D Weeks; Arthur Van Aerschot
Journal:  Int J Mol Sci       Date:  2021-02-10       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.